Outpatient parenteral antimicrobial therapy and antimicrobial stewardship: Challenges and checklists

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 4, 2014, Pages 965-970

  Gilchrist, M ^a   Seaton, R A ^b  

^a CHARING CROSS HOSPITAL   (United Kingdom)

^b GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

Author keywords

Ambulatory care; Clinical governance; Intravenous therapy

Indexed keywords

ANTIINFECTIVE AGENT; C REACTIVE PROTEIN; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; DAPTOMYCIN; ERTAPENEM; TEICOPLANIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL STEWARDSHIP; ANTIMICROBIAL THERAPY; ARTICLE; BODY TEMPERATURE; CLOSTRIDIUM DIFFICILE INFECTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG STABILITY; DRUG SURVEILLANCE PROGRAM; HEALTHCARE ASSOCIATED INFECTION; HOSPITAL ADMISSION; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; LENGTH OF STAY; LEUKOCYTE COUNT; OUTPATIENT CARE; OUTPATIENT PARENTERAL ANTIMICROBIAL THERAPY; PARENTERAL DRUG ADMINISTRATION; PATIENT CARE; PEPTOCLOSTRIDIUM DIFFICILE; PRACTICE GUIDELINE; QUALITY CONTROL; RISK BENEFIT ANALYSIS; RISK MANAGEMENT; UNITED KINGDOM; AMBULATORY CARE; BACTERIAL INFECTIONS; DRUG UTILIZATION; HEALTH CARE POLICY; INFUSION; OUTPATIENT; PROCEDURES; STANDARDS;

AMBULATORY CARE; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG UTILIZATION; GREAT BRITAIN; GUIDELINES AS TOPIC; HEALTH POLICY; HUMANS; INFUSIONS, PARENTERAL; OUTPATIENTS;

EID: 84926504933     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku517     Document Type: Article

References (32)

1. Rucher RW, Harrison GM. Outpatient intravenous medications in the management of cystic fibrosis. Pediatrics 1974; 54: 358-60.
2. Chapman ALN, Seaton RA, CooperMA et al. Good practice recommendations on out-patient parenteral antimicrobial therapy (OPAT) in adults in the UK: a consensus statement. J Antimicrob Chemother 2012; 67: 1053-62.
3. Matthews PC, Conlon CP, Berendt AR et al. Outpatient parenteral antimicrobial therapy (OPAT): is it safe for selected patients to self-administer at home? A retrospective analysis of a large cohort over 13 years. J Antimicrob Chemother 2008; 61: 226-7.
4. Chapman ALN, Dixon S, Andrews D et al. Clinical efficacy and costeffectiveness of outpatient parenteral antibiotic therapy (OPAT): a UK perspective. J Antimicrob Chemother 2009; 64: 1316-24.
5. Torok ME, Chapman AL, Lessing MP et al. Outpatient antimicrobial therapy: recent developments and future prospects. Curr Opin Investig Drugs 2010; 11: 929-39.
6. Poretz DM, Woolard D, Goldenberg LJ et al. Outpatient use of ceftriaxone: a cost-benefit analysis. Am J Med 1984; 77: 77-83.
7. Eisenberg JM, Kitz DS. Savings from outpatient antibiotic therapy for osteomyelitis: economic analysis of a therapeutic strategy. JAMA 1986; 255: 1584-8.
8. Yong C, Fisher DA, Sklar GE et al. A cost analysis of outpatient parenteral antibiotic therapy (OPAT): an Asian perspective. Int J Antimicrob Agents 2009; 33: 46-51.
9. WHO. Antimicrobial Resistance: Global Report on Surveillance, 2014. http://apps.who.int/iris/bitstream/10665/112642/1/9789241564748_eng.pdf?ua=1.
10. Ashiru-Oredope D, Sharland M, Charani E et al. Improving the quality of antibiotic prescribing in the NHS by developing a new Antimicrobial Stewardship Programme: Start Smart-Then Focus. J Antimicrob Chemother 2012; 67 Suppl 1: i51-63.
11. Nathwani D, Sneddon J, Malcolm W et al. Scottish Antimicrobial Prescribing Group (SAPG): development and impact of the Scottish National Antimicrobial Stewardship Programme. Int J Antimicrob Agents 2011; 38: 16-26.
12. Society for Healthcare Epidemiology of America, Infectious Diseases Society of America, Pediatric Infectious Diseases Society. Policy statement on antimicrobial stewardship by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS). Infect Control Hosp Epidemiol 2012; 33: 322-7.
13. Peloquin CA, Berning SE, Nitta AT et al. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clin Infect Dis 2004; 38: 1538-44.
14. Lamont E, Seaton RA, Macpherson M et al. Development of teicoplanin dosage guidelines for patients treated within an outpatient parenteral antibiotic therapy (OPAT) programme. J Antimicrob Chemother 2009; 64: 181-7.
15. Howden BP, Grayson ML. Hospital-in-the-home treatment of infectious diseases. Med J Aus 2002; 176: 440-5.
16. Chakraborty A, Roy S, Loeffler J. Comparison of the pharmacokinetics, safety and tolerability of daptomycin in healthy adult volunteers following intravenous administration by 30 min infusion or 2 min injection. J Antimicrob Chemother 2009; 64: 151-8.
17. Slimings C, Riley TV. Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother 2014; 69: 881-91.
18. Duncan CJ, Barr DA, Seaton RA. Outpatient parenteral antimicrobial therapy with ceftriaxone, a review. Int J Clin Pharm 2012; 34: 410-7.
19. Barr DA, Semple L, Seaton RA. Outpatient parenteral antimicrobial therapy (OPAT) in a teaching hospital-based practice: a retrospective cohort study describing experience and evolution over 10 years. Int J Antimicrob Agents 2012; 39: 407-13.
20. Patel S, Abrahamson E, Goldring S et al. Good practice recommendations for paediatric outpatient parenteral antibiotic therapy (p-OPAT) in the UK: a consensus statement. J Antimicrob Chemother 2015; 70: 360-73.
21. Tice AD, Rehm SJ, Dalovisio JR et al. Practice guidelines for outpatient parenteral antimicrobial therapy. Clin Infect Dis 2004; 38: 1651-72.
22. Dryden M, Saeed K, Townsend R et al. Antibiotic stewardship and early discharge from hospital: impact of a structured approach to antimicrobial management. J Antimicrob Chemother 2012; 67: 2289-96.
23. Seaton RA, Bell E, Gourlay Y et al. Nurse-led management of uncomplicated cellulitis in the community: evaluation of a protocol incorporating intravenous ceftriaxone. J Antimicrob Chemother 2005; 55: 764-7.
24. Garrett T, Harbort Y, Trebble M et al. Once or twice-daily, algorithmbased intravenous cephazolin for home-based cellulitis treatment. Emerg Med Australas 2012; 24: 383-92.
25. Krogsgaard MR, Hansen BA, Slotsbjerg T et al. Should probenecid be used to reduce the dicloxacillin dosage in orthopaedic infections? A study of the dicloxacillin-saving effect of probenecid. Pharmacol Toxicol 1994; 74: 181-4.
26. Desai M, Franklin BD, Holmes A et al. A new approach to treatment of resistant gram-positive infections: potential impact of targeted IV to oral switch on length of stay. BMC Infect Dis 2006; 6: 94.
27. Gilchrist M, Franklin BD, Patel J. An outpatient parenteral antibiotic therapy (OPAT) map to identify risks associated with an OPAT service. J Antimicrob Chemother 2008; 62: 177-83.
28. Seaton RA, Sharp E, Bezlyak V et al. Factors associated with outcome and duration of therapy in outpatient parenteral antibiotic therapy (OPAT) patients with skin and soft-tissue infections. Int J Antimicrob Agents 2011; 38: 243-8.
29. Duncan CJ, Barr DA, Ho A et al. Risk factors for failure of outpatient parenteral antibiotic therapy (OPAT) in infective endocarditis. J Antimicrob Chemother 2013; 68: 1650-4.
30. Nathwani D, Tice A. Ambulatory antimicrobial use: the value of an outcomes registry. J Antimicrob Chemother 2002; 49: 149-54.
31. BSAC. United Kingdom Outpatient Parenteral Antimicrobial Therapy Initiative. http://e-opat.com/outcomes-registry/.
32. Muldoon E, Snydman D, Penland E et al. Are we ready for an outpatient parenteral antibiotic therapy (OPAT) bundle? A critical appraisal of the evidence. Clin Infect Dis 2013; 57: 419-24.